Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060671 · ClinicalTrials.gov registry record · Phase 3
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
A Phase 3 study, sponsored by CTI BioPharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
NCT00060671: Clinical Trial Phase 3 study, sponsored by CTI BioPharma.
NCT00060671 is a Phase 3 study that was terminated before completion, run by CTI BioPharma. The registered enrollment target is 800 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060671, a Phase 3 study, was terminated before completion, sponsored by CTI BioPharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients' remission, compared to rituximab alone.
Interventions
- DRUG rituximab
- DRUG Pixantrone (BBR 2778)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060671
The ClinicalTrials.gov registry entry for NCT00060671 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT00060671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060671 about?
NCT00060671 is a clinical study titled "Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma". The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients' remission, compared to rituximab alone.
What is the current status of trial NCT00060671?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2005-01. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00060671?
The interventions under investigation include: rituximab (DRUG), Pixantrone (BBR 2778) (DRUG).
Who is sponsoring clinical trial NCT00060671?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.